pounds in addition to discovering many potentially novel cedures). Competitive growth of the mutant pool was carried out for 20 generations in media containing sedrug targets.
lected compounds ( Figure 1A ). Strain abundance was measured before and after outgrowth by hybridization Results of differentially labeled (Cy3/Cy5) barcode tags to DNA microarrays ( Figures 1B-1D ). Deletion strains that were Study Design Rationale The experimental strategy used to interrogate drug acsensitive to a given compound were outcompeted by thousands of unaffected strains in the pool. Compounds tivities in this study is outlined in Figure 1 . A mixture of isogenic yeast mutants was generated by pooling 3503 were administered at concentrations resulting in moderate growth inhibition to ensure that the activities of the heterozygous deletion strains engineered with strainspecific molecular barcode tags (see Experimental Proputative drug target(s) were rate limiting for growth. Un- (A) Compilation of signal intensity data for the ERG1 heterozygote barcode tag across all 78 drug treatments. The Cy3 (green) or Cy5 (red) signal intensities were obtained from tagspecific oligonucleotide features represented in triplicate on the microarray. In most drug treatments, the Cy3 and Cy5 intensities were roughly equal indicating that the strain abundance remained unchanged over the course of most drug treatments. In the terbinafine treatment, however, the Cy5 intensity is much lower than that of the Cy3 for the ERG1 heterozygote tag. This indicates that the relative abundance of the ERG1 heterozygote was depleted during outgrowth in the presence of terbinafine, which is known to inhibit Erg1p activity.
(B) Statistical significance of terbinafine-specific fitness changes in the pool. Hybridization data across all drug treatments were used to determine the average performance of each strain during outgrowth. A modified Student's t test was used to calculate confidence levels by comparing the fitness levels from individual treatments to the average performance across all treatments. The resulting P values for each strain in the terbinafine treatment are plotted on the x axis and the number of strains with a given P value are plotted on the y axis. Notice that the erg1/ ERG1 strain is the single outlier in the terbinafine treatment.
der these conditions, strains that are heterozygous for ments as indicated by the similarity of hybridization intensities before and after each of the competitive growth drug target genes have the greatest chance of displaying hypersensitivity phenotypes (Giaever et al., 1999) . experiments. However, the log 10 intensities of the amplified tags showed a significant reduction following treatment with terbinafine suggesting that the erg1/ERG1 Identifying Drug-Specific Growth Defects strain had been depleted from the population. Figure  A strain-specific error model was developed to distin-2B shows the results of log 10 P values for all 3503 strains guish between general and drug-dependent growth dein the pool following terbinafine treatment. The ERG1 fects. To accomplish this, a reference set was generated heterozygote was the most significant outlier with a P by calculating the mean performance of each strain value of less than 1 ϫ 10
Ϫ85
. across a large number of competitive growth experiments. Next, the scatter error for these measurements was calculated to determine the reproducibility of each Large-Scale Analysis of 78 Compounds This screen was initiated by testing commercially availstrain's performance. To identify strains with drug-specific changes in growth rates, the fitness values from a able compounds for the ability to inhibit growth in our yeast strain background (see Experimental Procedures given drug treatment were compared to the corresponding values in the reference set using a modified Stufor description). Seventy-eight compounds that induced moderate levels of growth inhibition (0.70 Յ pool dent's t test (see Experimental Procedures). The resulting P values reflect the probability that the observed fitness Յ 0.96; see Experimental Procedures for definition of pool fitness) were selected for analysis (Table 1) . growth rate in any given drug treatment could occur by chance based on the strain's behavior in the referThe compounds analyzed in this study included many clinically used therapeutic agents and agricultural ence set. Figure 2A shows an example of the hybridization data chemicals. Figure 3 shows an overview of the P value data for all 3503 strains across the 78 compound treatcollected for one of the heterozygotes (ERG1) before (Cy3) and after (Cy5) each of the 78 different competitive ments (also in Supplemental Table S1 available at http:// www.cell.com/cgi/content/full/116/1/121/DC1). Of the growth experiments. The 20 bp tags for each of the strains in the pool were printed in triplicate on the mi-78 compounds analyzed, 18 resulted in no drug-specific fitness changes (Group I), 56 resulted in a small number croarrays that were used for these experiments. In this example, the relative growth rate of the ERG1 heterozyof significant outliers (Group II), and 4 resulted in widespread fitness changes (Group III) compared to the refergote was not affected by the majority of the drug treat- revealed drug-induced haploinsufficiency for eight (Venema and Tollervey, 1999) . We monitored the removal of internal transcribed spacers, ITS1 and ITS2, genes that play roles in ribosome biogenesis in addition to the previously reported target CDC21 (Figure 6A) .
by Northern blot analysis using ITS-specific oligonucleotide probes ( Figure 6C ). We found that 5FU treatment Four of the seven genes (RRP6, RRP41, RRP44, and RRP46) encode components of the exosome, a concauses the accumulation of an rRNA processing product we refer to as A2-C2 ( Figure 6C ). In addition, 5FU treatserved complex required for 5.8S rRNA and snoRNA 3Ј end processing ( ure 6C). Next, we asked whether 5FU treatment enhanced the To further characterize the effect of 5FU, we monitored rRNA intermediates in normal and mutant yeast accumulation of A2-C2 in specific heterozygous deletion strains identified in this study. The wild-type control and strains following drug treatment. Figure 6B outlines the major events in rRNA processing, which begins with each of the heterozygotes were grown in the presence of 5FU followed by Northern blot analysis to measure synthesis of the 35S pre-rRNA by RNA polymerase I and proceeds by a series of endo-and exonucleolytic A2-C2 levels ( Figure 6D ). Strains that were heterozygous for components of the exosome (RRP6, RRP41, RRP44, cleavages that yield three of the four mature rRNAs figure (lanes 1-3) . RNA was also prepared from an untreated wild-type haploid (lane 4) and an isogenic rrp6::KAN mutant (lane 5). The blot was probed with radiolabeled oligonucleotides (indicted at the left of each image) complementary to specific pre-rRNA intermediates and mature 5.8S rRNA. Notation to the right of each image indicates the identity of the major pre-rRNA intermediates. and RRP46) produced 2-to 10-fold more A2-C2 than the Another advantage of the fitness assay is that biological processes that are affected by a given compound wild-type strain treated with 5FU ( Figure 6D ). Although there is evidence that 5FU may result in general RNA are identified in addition to the precise protein target(s). For example, treatment of the heterozygous deletion damage, our results reveal a specific molecular mechanism by which 5FU may inhibit cell growth through perpool with 5FU resulted in the identification of a group of genes that encode components of the exosome comturbation of rRNA processing by the exosome complex. In fact, preliminary data suggest that 5FU prolongs the plex. Another example involved the drug tunicamycin, which is known to affect protein glycosylation. Besides time yeast cells spend in G2/M and that this effect is exacerbated by the exosome mutations (data not identifying the known target (ALG7p), heterozygotes involved in either the endoplasmic reticulum (ER) stress shown).
response ( strain-specific error model to identify drug-dependent effects that are statistically significant. Since some hetLimitations and Technical Considerations erozygotes have nonspecific growth defects, it is necesWhile the fitness assay is a powerful approach for identisary to understand the normal behavior of each strain fying drug targets, there are also a number of limitations.
before calculating drug-induced effects. We determined First, the compound of interest must be able to affect that a reference set must be populated with a minimum the growth rate of the cell. Failure of a compound to of 50 experiments and that chemical treatments are impart a fitness defect may indicate that (1) the drug more effective compared to nontreated controls for the target is not encoded in the yeast genome; (2) drug reference set. When performed as described here, this effects are masked by other proteins with redundant method will detect as little as 5-10% growth deficits activities; (3) the drug was not correctly metabolized; or in individual strains (data not shown). However, it is (4) the drug was not able to enter the cell. However, the important to note that each study must generate its own ability of a compound to affect the growth rate of yeast reference set due to the inherent variability of experidoes not guarantee that a target will be identified by mental conditions. Sensitivity could theoretically be inthis approach. In order for this approach to work, a creased by extending the pool outgrowth beyond 20 heterozygote for the target gene must be present in the generations and by increasing the number of experimutant pool. Unfortunately, heterozygotes representing ments included in the reference set. We have also found only about half of the yeast genome were available at that P values from this approach provide an effective the time of this study, which resulted in a lower detection way to rank order the strains in a given drug treatment rate than would be expected from a full genome pool.
to identify the significant outliers. The ability to compare Failure to detect the precise protein targets of stauro-P values across compounds is limited by the fact that sporine (PKC1) and the sulfa-based drugs (FOL1 and compounds have very diverse modes of action and the FOL3) can be attributed to the fact that the target strains doses of different compounds cannot be considered were not in the pool. Another requirement of this assay equivalent. is that the activity level of the targeted protein must be influenced by the dosage level of the corresponding Future Directions gene under the conditions profiled. Finally, compounds
We have demonstrated that fitness profiling is a powerthat exert their effects through direct interaction with ful approach for studying the activities of clinically relenonprotein elements in the cell, such as DNA (actinomyvant compounds in yeast. Tagged heterozygous delecin D) or ergosterol (amphotericin B), do not appear tion strains have been made available for virtually every suitable for this approach. gene in the yeast genome since this study was comIn some cases, the increased drug sensitivities of hetpleted. This resource coupled with commercially availerozygotes are caused by indirect effects on the cell able tag arrays make it possible to extend this type of and do not represent primary drug targets. For instance, analysis to the full genome level. In addition, a similar members of the multidrug resistant (MDR) family of strategy using pools of homozygous deletion strains transporters (e.g., PDR5) were implicated in a number could be used to reveal targets that are currently masked of drug treatments. These nonessential efflux pumps by redundant activities. Growth conditions can also be act to reduce the effective intracellular concentration of modified to assess drug sensitivities of genes that are certain structural classes of compounds. Deletion of one expressed only under certain physiological conditions. of the two copies of these genes in a diploid cell can Recently developed techniques to introduce specific result in a reduced capacity to export drugs from the mutations into all strains of a deletion pool make it possicell, thereby causing a hypersensitivity phenotype of the ble to identify drug effects in a variety of different genetic sitivity to terbinafine (P value ϭ 1 ϫ 10 Ϫ16 ) indicating
